Skip to main content
SpringerLink
Log in

Pharmacology of Sleep

  • Chapter
  • First Online:
Essentials of Sleep Medicine

Part of the book series: Respiratory Medicine ((RM))

  • 1138 Accesses

Abstract

Drugs modulating sleep and wakefulness operate by modifying the activity of key sleep–wake brain neurotransmitters. This chapter reviews the pharmacology, efficacy, and potential adverse effects of drugs used for treating chronic insomnia. Similarly, it discusses wake-promoting agents, including newly developed drugs, indicated for the treatment of excessive daytime sleepiness, and enumerates novel drugs that are in development.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Eban-Rothschild A, Appelbaum L, de Lecea L. Neuronal mechanisms for sleep/wake regulation and modulatory drive. Neuropsychopharmacology. 2018;43(5):937–52.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Atkin T, Comai S, Gobbi G. Drugs for insomnia beyond benzodiazepines: pharmacology, clinical applications, and discovery. Pharmacol Rev. 2018;70(2):197–245.

    Article  CAS  PubMed  Google Scholar 

  3. Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother. 1998;32(6):680–91.

    Article  CAS  PubMed  Google Scholar 

  4. Roth T, Roehrs TA. A review of the safety profiles of benzodiazepine hypnotics. J Clin Psychiatry. 1991;52(Suppl):38–41.

    PubMed  Google Scholar 

  5. Mendelson WB. Clinical distinctions between long-acting and short-acting benzodiazepines. J Clin Psychiatry. 1992;53(Suppl):4–7; discussion 8–9.

    PubMed  Google Scholar 

  6. Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med. 2007;22(9):1335–50.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Glass J, Lanctôt KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331(7526):1169.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Winkler A, Auer C, Doering BK, Rief W. Drug treatment of primary insomnia: a meta-analysis of polysomnographic randomized controlled trials. CNS Drugs. 2014;28(9):799–816.

    Article  CAS  PubMed  Google Scholar 

  9. Baandrup L, Ebdrup BH, Rasmussen J, et al. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev. 2018;3:CD011481.

    PubMed  Google Scholar 

  10. Prescribers’ digital reference [Internet]. Whippany: PDR, L.L.C; 2020. zolpidem tartrate-Drug Summary; [cited 2020 July 31]; [about 1 page]. Available from: https://www.pdr.net/drug-summary/Ambien-zolpidem-tartrate-2515.

  11. VA/DoD Clinical Practice Guideline. The Management of Chronic Insomnia Disorder and Obstructive Sleep Apnea. Washington, DC: U.S. Government Printing Office; 2019. https://www.healthquality.va.gov/guidelines/CD/insomnia/index.asp.

    Google Scholar 

  12. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8(5):e63773.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Auger RR, Burgess HJ, Emens JS, Deriy LV, Thomas SM, Sharkey KM. Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders: advanced sleep-wake phase disorder (ASWPD), delayed sleep-wake phase disorder (DSWPD), non-24-hour sleep-wake rhythm disorder (N24SWD), and irregular sleep-wake rhythm disorder (ISWRD). An update for 2015: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2015;11(10):1199–236.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Erland LA, Saxena PK. Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content. J Clin Sleep Med. 2017;13(2):275–81.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Foley HM, Steel AE. Adverse events associated with oral administration of melatonin: A critical systematic review of clinical evidence. Complement Ther Med. 2019;42:65–81.

    Article  PubMed  Google Scholar 

  16. Prescribers’ digital reference [Internet]. Whippany: PDR, L.L.C; 2020. ramelteon-Drug Summary; [cited 2020 July 31]; [about 1 page]. Available from: https://www.pdr.net/drug-summary/Rozerem-ramelteon-562.

  17. Kuriyama A, Honda M, Hayashino Y. Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Med. 2014;15(4):385–92.

    Article  PubMed  Google Scholar 

  18. Liu L, Wang Q, Liu A, Lan X, Huang Y, Zhao Z, et al. Physiological implications of orexins/Hypocretins on energy metabolism and adipose tissue development. ACS Omega. 2020;5(1):547–55.

    Article  CAS  PubMed  Google Scholar 

  19. Prescribers’ digital reference [Internet]. Whippany: PDR, L.L.C; 2020. suvorexant -Drug Summary cited 2020 July 31]; Available from: https://www.pdr.net/drug-summary/Belsomra-suvorexant-3605

  20. Lemborexant. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf.

  21. Herring WJ, Snyder E, Budd K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012;79(23):2265–74.

    Article  CAS  PubMed  Google Scholar 

  22. Patel KV, Aspesi AV, Evoy KE. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia. Ann Pharmacother. 2015;49(4):477–83.

    Article  CAS  PubMed  Google Scholar 

  23. Kuriyama A, Tabata H. Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis. Sleep Med Rev. 2017;35:1–7.

    Article  PubMed  Google Scholar 

  24. Citrome L. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2014;68(12):1429–41.

    Article  CAS  PubMed  Google Scholar 

  25. Rosenberg R, Murphy P, Zammit G, et al. Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: A phase 3 randomized clinical trial. JAMA Netw Open. 2019;2(12):e1918254.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Kärppä M, Yardley J, Pinner K, et al. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep. 2020;43(3)

    Google Scholar 

  27. Kishi T, Nomura I, Matsuda Y, et al. Lemborexant vs suvorexant for insomnia: A systematic review and network meta-analysis. J Psychiatr Res. 2020;128:68–74.

    Article  PubMed  Google Scholar 

  28. Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(5):461–71.

    Article  CAS  PubMed  Google Scholar 

  29. Thompson C. Onset of action of antidepressants: results of different analyses. Hum Psychopharmacol. 2002;17(Suppl 1):S27–32.

    Article  CAS  PubMed  Google Scholar 

  30. Yeung WF, Chung KF, Yung KP, Ng TH. Doxepin for insomnia: a systematic review of randomized placebo-controlled trials. Sleep Med Rev. 2015;19:75–83.

    Article  PubMed  Google Scholar 

  31. American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatric Society 2019 Update AGS Beers Critieria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–94.

    Google Scholar 

  32. Fung SJ, Yamuy J, Sampogna S, Morales FR, Chase MH. Hypocretin (orexin) input to trigeminal and hypoglossal motoneurons in the cat: a double-labeling immunohistochemical study. Brain Res. 2001;903(1):257–62.

    Article  CAS  PubMed  Google Scholar 

  33. Everitt H, Baldwin DS, Stuart B, Lipinska G, Mayers A, Malizia AL, et al. Antidepressants for insomnia in adults. Cochrane Database Syst Rev. 2018;5:CD010753.

    PubMed  Google Scholar 

  34. Yi XY, Ni SF, Ghadami MR, Meng HQ, Chen MY, Kuang L, et al. Trazodone for the treatment of insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med. 2018;45:25–32.

    Article  PubMed  Google Scholar 

  35. Full prescribing information: Desyrel. U.S. Food and Drug Administration; 2017.

    Google Scholar 

  36. Thompson W, Quay TAW, Rojas-Fernandez C, Farrell B, Bjerre LM. Atypical antipsychotics for insomnia: a systematic review. Sleep Med. 2016;22:13–7.

    Article  PubMed  Google Scholar 

  37. Prescribers’ digital reference [Internet]. Whippany: PDR, L.L.C; 2020. quetiapine -Drug Summary cited 2020 July 31]; Available from: https://www.pdr.net/drug-summary/Seroquel-quetiapine-fumarate-2185.

  38. Raiteri M, Bertollini A, Angelini F, Levi G. d-Amphetamine as a relaeser of reuptake inhibitor of biogenic amines in SYnaptosomes. Eru J Pharmacol. 1975;34:189–95.

    Article  CAS  Google Scholar 

  39. Nicholson A, Stone BM. Heterocyclic amphetamine derivatives and caffenine on sleep in man. Br J Clin Pharmacol. 1980;9(2):195–203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30(12):1705–11.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Lammers GJ. Drugs used in narcolepsy and other hypersomnias. Sleep Med Clin. 2018;13(2):183–9.

    Article  PubMed  Google Scholar 

  42. Murillo-Rodríguez E, Barciela Veras A, Barbosa Rocha N, et al. An overview of the clinical uses, pharmacology, and safety of modafinil. ACS Chem Neurosci. 2018;9(2):151–8.

    Article  CAS  PubMed  Google Scholar 

  43. Golicki D, Bala MM, Nieanda M, Wierzbika A. Modafinil for narcolepsy: systemic review and meta-analysis. Med Sci Monit. 2010;16(8):177–86.

    Google Scholar 

  44. Moldofsky H, Broughton R, Hill J. A randomized trial of the ling-term, continued efficacy and safety of modafinil in marcolepsy. Sleep Med. 2000;1:109–16.

    Article  CAS  PubMed  Google Scholar 

  45. Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep. 2006;29(7):939–46.

    Article  PubMed  Google Scholar 

  46. Schwartz J, Feldman N, Bogan R, Nelson M, Huges R. Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy. Clin Neurpharmacol. 2003;164(9):252–7.

    Article  Google Scholar 

  47. Chapman JL, Vakulin A, Hedner J, Yee BJ, Marshall NS. Modafinil/armodafinil in obstructive sleep apnoea: a systematic review and meta-analysis. Eur Respir J. 2016;47(5):1420–8.

    Article  PubMed  Google Scholar 

  48. Czeisler CA, Walsh JK, Roth T, et al. Modafinil for excessive sleepiness associated with shift-work sleep disorder. N Engl J Med. 2005;353(5):476–86.

    Article  CAS  PubMed  Google Scholar 

  49. Hirshkowitz M, Black J, Wesnes K, et al. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respir Med. 2007;101(3):616–27.

    Article  CAS  PubMed  Google Scholar 

  50. Roth T, White D, Schmidt-Nowara W, et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obsturctive sleep apnea/hypopnea syndrome: A 12-week, mulitcenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther. 2006;28(5):689–706.

    Article  CAS  PubMed  Google Scholar 

  51. Harsh J, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin. 2006;22(4):761–74.

    Article  CAS  PubMed  Google Scholar 

  52. Czeisler C, Walsh J, Wesnes K, Arora S, Roth T. Armodafinil for treatment of excessive sleepiness associated with shift-work disorder: a randomized controlled study. Mayo Clin Proc. 2009;84(11):958–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Black J, Hull S, Tiller J, Yng R, Harsh J. The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: and open-label extension study. J Clin Sleep Med. 2010;6(5):458–66.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Schwartz J, Kahn A, McCall W, Weintraub J, Tiller J. Tolerability and efficacy of armodafinil in naive patients with excessive sleepiness associated with obsturctive sleep apnea, shift work, disorder, or narcolepsy: a 12-month, open-label, flexiable-does study with an extension period. J Clin Sleep Med. 2010;6(5):450–7.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Rosenberg R, Bogan R, Tiller J, et al. A phase 3, double-blind, randomized, placebo-controlled study of armodafinil for excessive sleepiness associated with jet lag disorder. Mayo Clin Proc. 2010;85(7):630–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Roth T, Schwartz J, Hirshkowitz M, et al. Evaluation of the safety of modafinil for treatment of excessive sleepiness. J Clin Sleep Med. 2007;75(20):595–602.

    Article  Google Scholar 

  57. Rossetti A, Heinzer R, Tafti M, Buclin T. Rapic occurance of depression following addition of sodium oxybate. Sleep Med. 2010;11:500–1.

    Article  PubMed  Google Scholar 

  58. Xyrem (sodium oxybate) [prescribing information]. Palo Alto: Jazz Pharmaceuticals; September 2020. Xywav (calcium, magnesium, potassium, and sodium oxybates) October 2020.

    Google Scholar 

  59. Boscolo-Berto R, Viel G, Montagnese S, et al. Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev. 2012;16(5):431–43.

    Article  PubMed  Google Scholar 

  60. Black J, Pardi D, Hornfeldt C, Inhaber N. The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy. Sleep Med. 2009;10(8):829–35.

    Article  PubMed  Google Scholar 

  61. Bogan RK, Thorpy MJ, Dauvilliers Y, et al. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy. Sleep. 2021;44(3)

    Google Scholar 

  62. Alshaikh MK, Tricco AC, Tashkandi M, et al. Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis. J Clin Sleep Med. 2012;8(4):451–8.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med. 2005;1(4):391–7.

    Article  Google Scholar 

  64. The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawl symptoms. J Toxicol Clin Toxicol 2003;41:131–5.

    Google Scholar 

  65. Thorpy MJ, Shapiro C, Mayer G, et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol. 2019;85(3):359–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Schweitzer PK, Rosenberg R, Zammit GK, et al. Solriamfetol for excessive sleepiness in obstructive sleep apnea (TONES 3). A RCT. Am J Respir Crit Care Med. 2019;199(11):1421–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Thorpy MJ, Bogan RK. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications. Sleep Med. 2020;68:97–109.

    Article  PubMed  Google Scholar 

  68. Dauviliers Y, Bassetti C, Lammers GJ, Amulf I, Mayer G, Rodenbeck A, Lehert P, Ding CL, Lecomte JM, Schwartz JC, HARMONY I Study Group. Pitolisant versus placebo or Modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013;12(11):1068–75.

    Article  CAS  Google Scholar 

  69. Kollb-Sielecka M, Demolis P, Emmerich J, Markey G, Salmonson T, Haas M. The European medicines agency review of pitolisant for treatment of narcolepsy. Sleep Med. 2017;33:125–9.

    Article  PubMed  Google Scholar 

  70. Bouryi VA, Lewis DI. The modulation by 5-HT of glutamatergic inputs from the raphe pallidus to rat hypoglossal motoneurones, in vitro. J Physiol. 2003;553(3):1019–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013;13(2):214–23.

    PubMed  PubMed Central  Google Scholar 

  72. Janto K, Prichard JR, Pusalavidyasagar S. An update on dual orexin receptor antagonists and their potential role in insomnia therapeutics. J Clin Sleep Med. 2018;14(8):1399–408.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Reynolds AP, Adams R. Treatment of sleep disturbance in older adults. J Pharm Pract Res. 2019;49(3):296–304.

    Article  Google Scholar 

  74. Wichniak A, Wierzbicka A, Walęcka M, et al. Effects of antidepressants on sleep. Curr Psychiatry Rep. 2017;19:63.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Snyder E, Ma J, Svetnik V, Connor KM, et al. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data. Sleep Med. 2016;19:93–100.

    Article  PubMed  Google Scholar 

  76. Prescribers’ digital reference [Internet]. Whippany: PDR, L.L.C; 2020. zaleplon -Drug Summary cited 2020 July 31]; Available from: https://www.pdr.net/drug-summary/Sonata-zaleplon-1491.

  77. Prescribers’ digital reference [Internet]. Whippany: PDR, L.L.C; 2020. eszopiclone -Drug Summary cited 2020 July 31]; Available from: https://www.pdr.net/drug-summary/Lunesta-eszopiclone-2082.

  78. Ghaffari N, Robertson PA. Caution in prescribing modafinil and armodafinil to individuals who could become pregnant. JAMA Intern Med. 2021;181(2):277–8.

    Article  PubMed  Google Scholar 

  79. U.S. National Library of Medicine. ClinicalTrials.gov [Internet]. Bethesda. MD. [cited 2020 July 30.] Available from: https://clinicaltrials.gov/.

Download references

Acknowledgments

Merit Review Award, Department of Veterans Affairs, Grant #1I01CX001938-01.

Author information

Authors and Affiliations

  1. Pharmacy Benefits Management Services, Veterans Health Administration, Washington, D.C, USA

    Janet H. Dailey

  2. Sleep Medicine Section, Medical Service John D. Dingell VA Medical Center, Detroit, MI, USA

    Susmita Chowdhuri

  3. Department of Medicine, Wayne State University, Detroit, MI, USA

    Susmita Chowdhuri

Authors
  1. Janet H. Dailey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susmita Chowdhuri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susmita Chowdhuri .

Editor information

Editors and Affiliations

  1. Department of Internal Medicine Wayne State University School of Medicine, John D. Dingell VA Medical Center, Detroit, MI, USA

    M. Safwan Badr

  2. Geriatric Research Education and Clinical Center, Veteran Affairs Greater Los Angeles Healthcare System, Department of Medicine David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

    Jennifer L. Martin

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Dailey, J.H., Chowdhuri, S. (2022). Pharmacology of Sleep. In: Badr, M.S., Martin, J.L. (eds) Essentials of Sleep Medicine. Respiratory Medicine. Humana, Cham. https://doi.org/10.1007/978-3-030-93739-3_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-93739-3_2

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-93738-6

  • Online ISBN: 978-3-030-93739-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation